March 14, 2023
2 min learn
Beronilla MD, et al. Summary 502. Introduced at: AAAAI Annual Assembly; Feb. 24-27, 2023; San Antonio.
Beronilla experiences no related monetary disclosures.
SAN ANTONIO — Sufferers with bronchial asthma in an inner-city inhabitants had extra favorable COVID-19 outcomes than sufferers who didn’t have bronchial asthma, in accordance with information introduced on the American Academy of Allergy, Bronchial asthma & Immunology Annual Assembly.
“Few research have examined COVID-19 an infection particularly in inner-city sufferers with bronchial asthma,” Mydalyn D. Beronilla, MPH, medical analysis specialist with the Montefiore Well being System, mentioned throughout her presentation.
The retrospective examine examined the COVID-19 outcomes of two,373 adults with bronchial asthma handled within the allergy and immunology clinics of Montefiore Medical Middle within the Bronx, New York. COVID-19 standing was obtainable for 972 (41%) of those sufferers, with 221 (23%; 87% girls; imply age, 52 years; normal deviation [SD], 15.8) deemed optimistic.
“COVID-19 standing was established by way of optimistic [polymerase chain reaction] or by possessing optimistic COVID-19 antibodies,” Beronilla mentioned.
Additionally, 155 (72%) of the 216 sufferers who had pores and skin testing information had been atopic. These sufferers had a imply age of 51 years. Bronchial asthma severities ranged from gentle (n = 57; 37%) to reasonable (n = 64; 41%) and extreme (n = 34; 22%).
Bronchial asthma severities among the many 61 (91% girls; imply age, 52 years) sufferers with nonatopic bronchial asthma ranged from gentle (n = 32; 52%) to reasonable (n = 23; 38%) and extreme (n = 6; 10%).
The researchers moreover evaluated 11,224 sufferers (54% girls; imply age, 55 years; SD, 18.2) with COVID-19 who didn’t have bronchial asthma or COPD, together with 3,337 (30%) who had been hospitalized, of which 1,053 (32%) died.
In distinction, 26 (12%) of the sufferers with bronchial asthma and COVID-19 had been hospitalized, and three (12%) of those that had been hospitalized died.
“The general mortality fee amongst non-asthma, non-COPD sufferers was 9.4% vs. a fee of simply 1.4% within the bronchial asthma cohort,” Beronilla mentioned.
Extra particularly, 14 (9%) of the 155 sufferers with atopic bronchial asthma required hospitalization in contrast with 12 (20%) of the 61 sufferers who had nonatopic bronchial asthma. Two (14%) of the sufferers with atopic bronchial asthma who had been hospitalized and one (8%) of the sufferers with nonatopic bronchial asthma who had been hospitalized died.
“Dying fee was barely larger within the atopic group, however total numbers had been small, thus making it tough to attract conclusions,” Beronilla mentioned.
These findings point out extra favorable outcomes amongst sufferers with bronchial asthma within the inside metropolis, with decrease hospitalization charges notably for sufferers with atopic bronchial asthma, in contrast with sufferers who would not have bronchial asthma or COPD.